Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Investment in American manufacturing is on the rise, with pharmaceutical giant Merck recently announcing a landmark $1 billion investment to establish a manufacturing plant in Wilmington, Delaware.

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and ...

Merck was a detractor despite "solid" first-quarter results, as it "disappointed the market" with a more subdued outlook for the rest of the year as it trimmed earlier guidance amid a slowdown in ...

Merck & Co, a leading healthcare giant, has seen its shares plummet by 30% over the past year. Investors generally view the ...

Merck leans on Keytruda growth and pipeline expansion, Palo Alto rides subscription security demand, and Freeport benefits ...